Antibiotics for the treatment of hepatic encephalopathy

Rifaximin Treatment in Hepatic Encephalopathy

Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300 · see citing works

Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

Conn, H. O., Leevy, C. M., Vlahcevic, Z. R., Rodgers, J. B., Maddrey, W. C., Seeff, L. B., & Levy, L. L. (1977) · PubMed · Cited by 641 · see citing works

Comparison of Lactulose and Neomycin in the Treatment of Chronic Portal-Systemic Encephalopathy

Conn, H. O., Leevy, C. M., Vlahcevic, Z. R., Rodgers, J. B., Maddrey, W. C., Seeff, L. B., & Levy, L. L. (1977) · Gastroenterology · doi:10.1016/s0016-5085(77)80135-2 · Cited by 630 · see citing works

Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study

Fernández, J., Acevedo, J., Castro, M., Garcia, O., de Lope, C. R., Roca, D., Pavesi, M., Sola, E., Moreira, L., Silva, A., et al. (2012) · Hepatology · doi:10.1002/hep.25532 · Cited by 620 · see citing works

Hepatic encephalopathy

Blei, A. T., & Córdoba, J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03964.x · Cited by 527 · see citing works

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation

Bajaj, J. S., Hylemon, P. B., Ridlon, J. M., Heuman, D. M., Daita, K., White, M. B., Monteith, P., Noble, N. A., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00152.2012 · Cited by 525 · see citing works

Severe sepsis in cirrhosis†

Gustot, T., Durand, F., Lebrec, D., Vincent, J., & Moreau, R. (2009) · Hepatology · doi:10.1002/hep.23264 · Cited by 439 · see citing works

Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience: Hepatology

Bajaj, J. S., O'Leary, J. G., Reddy, K. R., Wong, F., Olson, J. C., Subramanian, R. M., Brown, G., Noble, N. A., Thacker, L. R., Kamath, P. S., et al. (2012) · Hepatology · doi:10.1002/hep.25947 · Cited by 413 · see citing works

Review article: the burden of hepatic encephalopathy

Poordad, F. F. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1746-6342.2006.03215.x · Cited by 401 · see citing works

Mechanisms, diagnosis and management of hepatic encephalopathy

Prakash, R., & Mullen, K. D. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.116 · Cited by 325 · see citing works

Hepatogastroenterology

Li, P., Wang, D., Wang, L., et al. (2012) · Hepatogastroenterology · doi:10.5754/hge12156 · Cited by 292 · see citing works

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis

Shawcross, D. L., Sharifi, Y., Canavan, J. B., Yeoman, A. D., Abeles, R. D., Taylor, N. J., Auzinger, G. M., Bernal, W. E., & Wendon, J. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.045 · Cited by 277 · see citing works

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy

Atterbury, C. E., Maddrey, W. C., & Conn, H. O. (1978) · Digestive Diseases and Sciences · doi:10.1007/bf01072921 · Cited by 267 · see citing works

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

Mas, A., Rodés, J., Sunyer, L., Rodrigo, L., Planas, R., Vargas, V., Castells, L., Rodrı́guez-Martı́nez, D., Fernández‐Rodríguez, C., Coll, I., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00350-1 · Cited by 253 · see citing works

Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)

Sidhu, S. S., Goyal, O., Mishra, B. P., Sood, A., Chhina, R. S., & Soni, R. K. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.455 · Cited by 244 · see citing works

Review article: the modern management of hepatic encephalopathy

BAJAJ, J. S. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04211.x · Cited by 243 · see citing works

Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy

Bajaj, J. S., Heuman, D. M., Wade, J. B., Gibson, D. P., Saeian, K., Wegelin, J. A., Hafeezullah, M., Bell, D. E., Sterling, R. K., Stravitz, R. T., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.061 · Cited by 243 · see citing works

In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009

Stepanova, M., Mishra, A., Venkatesan, C., et al. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.05.016 · Cited by 231 · see citing works

Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy

Leevy, C. B., & Phillips, J. A. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9442-4 · Cited by 162 · see citing works

Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

Jiang, Z., & DuPont, H. L. (2005) · Chemotherapy · doi:10.1159/000081991 · Cited by 158 · see citing works

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study

Sanyal, A. J., Younossi, Z. M., Bass, N. M., Mullen, K., Poordad, F. F., Brown, R. S., Vemuru, R. P., Jamal, M. M., Huang, S. C.-C., Merchant, K., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04808.x · Cited by 146 · see citing works

Treatment of hepatic encephalopathy with metronidazole.

MORGAN, M. H., Read, A. E., & Speller, D. C. E. (1982) · Gut · doi:10.1136/gut.23.1.1 · Cited by 143 · see citing works

Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

Strauss, E., Tramote, R., Silva, E. P., et al. (1992) · PubMed · Cited by 138 · see citing works

Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis

Bajaj, J. S., Pinkerton, S. D., Sanyal, A. J., et al. (2011) · Hepatology · doi:10.1002/hep.25507 · Cited by 137 · see citing works

Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites

Kalambokis, G. N., Mouzaki, A., Rodi, M., Pappas, K., Fotopoulos, A., Xourgia, X., & Tsianos, E. V. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.025 · Cited by 130 · see citing works

Double-blind, double-dummy comparison between treatment andwith rifaximin and lactulose in patients with medium to severe patients with medium to severe

Bucci, L., & Palmieri, G. (1993) · Current Medical Research and Opinion · doi:10.1185/03007999309111539 · Cited by 130 · see citing works

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

Paik, Y., Lee, K. S., Han, K., Song, K. H., Kim, M. H., Moon, B. S., Ahn, S. H., Lee, S. J., Park, H., Lee, D. K., et al. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.3.399 · Cited by 124 · see citing works

Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis

Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M., & Matteuzzi, D. (2002) · Journal of Chemotherapy · doi:10.1179/joc.2002.14.3.290 · Cited by 88 · see citing works

The cost‐effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysis

Huang, E.-J., Esrailian, E., & Spiegel, B. M. R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03464.x · Cited by 80 · see citing works

Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety

Festi, D., Mazzella, G., Orsini, M., Sottili, S., Sangermano, A., Bassi, S. L., Parini, P., Ferrieri, A., Falcucci, M., Grossi, L., et al. (1993) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80681-2 · Cited by 75 · see citing works

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy.

Tarao, K., Ikeda, T., Hayashi, K., Sakurai, A., Okada, T., Ito, T., Karube, H., Nomoto, T., MIZUNO, T., & Shindo, K. (1990) · Gut · doi:10.1136/gut.31.6.702 · Cited by 73 · see citing works

A Current Review of the Diagnostic and Treatment Strategies of Hepatic Encephalopathy

Poh, Z., & Chang, J. P.-E. (2012) · International Journal of Hepatology · doi:10.1155/2012/480309 · Cited by 73 · see citing works

Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy

Orlandi, F., Freddara, U., Candelaresi, M. T., Morettini, A., Corazza, G. R., Simone, A. D., Dobrilla, G., & Cavallini, G. (1981) · Digestive Diseases and Sciences · doi:10.1007/bf01308097 · Cited by 67 · see citing works

A non-absorbable rifamycin for treatment of hepatic encephalopathy.

Testa, R., Eftimiadi, C., Sukkar, G. S., et al. (1985) · PubMed · Cited by 58 · see citing works

Drug Therapy: Rifaximin

Bajaj, J. S., & Riggio, O. (2010) · Hepatology · doi:10.1002/hep.23866 · Cited by 54 · see citing works

Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy

Riggio, O., Mannaioni, G., Ridola, L., et al. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.738 · Cited by 52 · see citing works

Rifaximin in the treatment of hepatic encephalopathy

Iadevaia, M. D., Iadevaia, M. D., Cesaro, Prete, D., Gaeta, & Zulli, C. (2011) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s11988 · Cited by 49 · see citing works

Metronidazole Pharmacokinetics in Patients with Hepatic Encephalopathy

Loft, S. H., Sonne, J., Døssing, M., et al. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528708991867 · Cited by 49 · see citing works

Outcomes in Adult and Pediatric Liver Transplantation Among Various Ethnic Groups

Neff, G. W., Kemmer, N. M., Kaiser, T., et al. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.09.031 · Cited by 45 · see citing works

Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy

Parini, P., Cipolla, A., Ronchi, M., et al. (1992) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80433-3 · Cited by 40 · see citing works

Durability of Rifaximin Response in Hepatic Encephalopathy

Neff, G. W., Jones, M., Broda, T. R., et al. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318231faae · Cited by 27 · see citing works

Rifaximin for the Treatment of Hepatic Encephalopathy

Mantry, P., & Munsaf, S. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.09.173 · Cited by 27 · see citing works

Rifaximin in collateral treatment of port-systemic encephalopathy: a preliminary report

MARCO, F. D., Amato, P., & D’Arienzo, A. (1984) · Current Therapeutic Research · Cited by 27 · see citing works

Review article: β‐adrenoceptor blockers for the treatment of portal hypertension

Burroughs, A. K., Sprengers, D., & McCormick, P. A. (1987) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1987.tb00601.x · Cited by 18 · see citing works

Rifaximin in hepatic encephalopathy: More than just a non-absorbable antibiotic?

Jalan, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.002 · Cited by 15 · see citing works

Review: Rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy

Alcorn, J. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-02011 · Cited by 14 · see citing works

195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY

Sanyal, A. J., Bass, N. M., Poordad, F., et al. (2010) · Journal of Hepatology · doi:10.1016/s0168-8278(10)60197-3 · Cited by 10 · see citing works

Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis

Rusch, J. A., Layden, B. T., & Dugas, L. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130689 · Cited by 415 · see citing works

Microbiota-gut-brain axis and cognitive function

Gareau, M. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-0897-4_16 · Cited by 189 · see citing works

Promises of microbiome-based therapies

Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119 · see citing works

Hepatic Encephalopathy Involves Interactions Among the Microbiota, Gut, Brain

Victor, D. W., & Quigley, E. M. M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.022 · Cited by 12 · see citing works

Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.

Ahire, K., & Sonawale, A. (2017) · PubMed · Cited by 11 · see citing works

Is Lactulose Plus Rifaximin Better Than Lactulose Alone In The Management Of Hepatic Encephalopathy?

Butt, N. I., Butt, U. I., Kakar, A. A. T. K., et al. (2018) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2018.02.115 · Cited by 14 · see citing works

Rifaximin for the Treatment of Hepatic Encephalopathy

Mantry, P., & Munsaf, S. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.09.173 · Cited by 27 · see citing works

Lactulose and Rifaximin as Prevention for Recurrence Hepatic Encephalopathy

Marsigit, J., & Maulahela, H. (2018) · Advanced Science Letters · doi:10.1166/asl.2018.12674

A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.

Hasan, S., Datta, S., Bhattacherjee, S., Banik, S., Saha, S., & Bandyopadhyay, D. (2018) · PubMed · Cited by 7 · see citing works